Alejandro Pedroza-Montero
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alejandro Pedroza-Montero has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Alejandra Tapia-Villasenor
PhD Program in Nanotechnology, Physicas Deparment, University of Sonora, Blvd Luis Encinas y Rosales S/N, Col. Centro, Hermosillo 83000, Sonora, Mexico
1 shared publication - Annel Armenta-Gamez
PhD Program in Nanoscience, Center for Scientific Research and Higher Education of Ensenada (CICESE), Carretera Ensenada-Tijuana No. 3918, Zona Playitas, Ensenada 22860, Baja California, Mexico
1 shared publication - Erika Silva-Campa
Universidad de Sonora
1 shared publication - Hector Loro
Faculty of Sciences, National University of Engineering, Lima, Peru
1 shared publication - Karla Santacruz-Gomez
Physics Department, Universidad de Sonora, Hermosillo 85890, Sonora, Mexico
1 shared publication - Rodrigo Melendrez-Amavizca
Department of Physics Research, University of Sonora, Blvd Luis Encinas y Rosales S/N, Col. Centro, Hermosillo 83000, Sonora, Mexico
1 shared publication
Latest Publications
- Open Access
- 28 February 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (3) , 310
Gold Nanorods Embedded in Mesoporous Silica for Photothermal Therapy and SERS Monitoring in T47D Breast Cancer Cells
Background: The development of plasmonic photothermal therapy (PPTT) to trigger cancer cells is often hindered by uncontrolled overheating and the lack of real-time feedback. Methods: In this study, we report the synthesis of gold nanorod-embedded mesoporous silica nanoshells (AuNR@Si) as a multifunctional theranostic platform designed for controlled hyperthermia and surface-enhanced Raman spectroscopy (SERS) monitoring. Using a layer-by-layer templating strategy, AuNRs were successfully obtained within a hollow silica architecture. Results: While AuNRs alone exhibited rapid photothermal spikes reaching 64 °C, the AuNR@Si platform moderated the photothermal response, maintaining a stable therapeutic window (41–45 °C). In vitro assays using T47D breast cancer cells demonstrated a 33% reduction in viability following irradiation. Furthermore, the structural stability of the AuNR@Si platform enabled SERS monitoring of cellular damage, identifying specific biochemical fingerprints of protein denaturation, cytochrome c release and DNA fragmentation. Conclusions: These results suggest that AuNR@Si nanoshells provide a safer, regulated approach to photothermal ablation with the added benefit of molecular detection, demonstrating proof-of-concept theranostic functionality in a luminal breast cancer model.
- 28 February 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (3) , 310
Open AccessGold Nanorods Embedded in Mesoporous Silica for Photothermal Therapy and SERS Monitoring in T47D Breast Cancer Cells
Background: The development of plasmonic photothermal therapy (PPTT) to trigger cancer cells is often hindered by uncontrolled overheating and the lack of real-time feedback. Methods: In this study, we report the synthesis of gold nanorod-embedded mesoporous silica nanoshells (AuNR@Si) as a multifunctional theranostic platform designed for controlled hyperthermia and surface-enhanced Raman spectroscopy (SERS) monitoring. Using a layer-by-layer templating strategy, AuNRs were successfully obtained within a hollow silica architecture. Results: While AuNRs alone exhibited rapid photothermal spikes reaching 64 °C, the AuNR@Si platform moderated the photothermal response, maintaining a stable therapeutic window (41–45 °C). In vitro assays using T47D breast cancer cells demonstrated a 33% reduction in viability following irradiation. Furthermore, the structural stability of the AuNR@Si platform enabled SERS monitoring of cellular damage, identifying specific biochemical fingerprints of protein denaturation, cytochrome c release and DNA fragmentation. Conclusions: These results suggest that AuNR@Si nanoshells provide a safer, regulated approach to photothermal ablation with the added benefit of molecular detection, demonstrating proof-of-concept theranostic functionality in a luminal breast cancer model.